Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | MAFG | O15525 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27353701 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL30696779 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL27353872 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL30696802 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL30696712 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL30696801 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL30696825 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL30696789 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL30696749 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL27353390 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBMAFGHPGDNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4543439-A2 | NRF2 PROTEIN DEGRADERS | Ganymede Oncology, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024006742-A2 | NRF2 PROTEIN DEGRADERS | DRACEN PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | SMN1; SMN2 2342/4885POLB 1621/4885MAFG 448/4885 |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | SMN1; SMN2 1515/4885POLB 1234/4885MAFG 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.